Q2 EPS Forecast for Ovid Therapeutics Reduced by Analyst

Ovid Therapeutics (NASDAQ:OVID) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of Ovid Therapeutics in a research report issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.10) per share for the quarter, down from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.41) EPS and FY2027 earnings at ($0.35) EPS.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). Ovid Therapeutics had a negative return on equity of 22.51% and a negative net margin of 240.11%.

Several other research analysts have also recently issued reports on OVID. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Ovid Therapeutics in a research report on Wednesday, April 15th. Wall Street Zen raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Ovid Therapeutics in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Tuesday, April 21st. Finally, Roth Mkm reissued a “buy” rating and issued a $7.00 target price on shares of Ovid Therapeutics in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $5.13.

Ovid Therapeutics Trading Up 3.7%

NASDAQ:OVID opened at $2.54 on Thursday. The stock has a 50-day simple moving average of $2.57 and a 200-day simple moving average of $1.95. The stock has a market cap of $474.07 million, a P/E ratio of -8.76 and a beta of 0.18. Ovid Therapeutics has a 1 year low of $0.27 and a 1 year high of $3.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 10.17 and a current ratio of 10.17.

Institutional Trading of Ovid Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new stake in Ovid Therapeutics during the 1st quarter valued at approximately $23,732,000. RA Capital Management L.P. purchased a new position in shares of Ovid Therapeutics during the 4th quarter worth approximately $17,464,000. Affinity Asset Advisors LLC raised its stake in shares of Ovid Therapeutics by 48.8% during the 1st quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock worth $23,613,000 after buying an additional 3,486,318 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Ovid Therapeutics by 6.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 4,544,113 shares of the company’s stock worth $10,088,000 after buying an additional 259,113 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new position in shares of Ovid Therapeutics during the 4th quarter worth approximately $6,985,000. 72.24% of the stock is owned by hedge funds and other institutional investors.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.